Minute Insight: Quest Diagnostics To Acquire Haystack Oncology For $300M In Cash

Quest Diagnostics will buy liquid biopsy start-up Haystack Oncology for a total of $450m with plans to launch a cancer-detection test in 2024.

Minute Insight
• Source: Informa/Alamy

Quest Diagnostics Incorporated is buying cancer-detection company Haystack Oncology for $300m in cash with plans to launch their liquid biopsy test in 2024, the companies announced on 27 April.

Baltimore-based Haystack Oncolgy, whose liquid biopsy technology is based on research from renowned Johns Hopkins University oncologists Bert Vogelstein, Ken Kinzler and Nickolas Papadopoulos, has developed a test to detect...

More from Minute Insights

More from Medtech Insight